OTCMKTS:VIVXF Avivagen (VIVXF) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free VIVXF Stock Alerts $0.0064 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.0064▼$0.006450-Day Range N/A52-Week Range$0.00▼$0.02VolumeN/AAverage Volume20,536 shsMarket Capitalization$497,216.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsShort InterestStock AnalysisChartEarningsShort Interest Get Avivagen alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Avivagen Stock (OTCMKTS:VIVXF)Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.Read More VIVXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIVXF Stock News HeadlinesApril 27, 2024 | seekingalpha.comCYTO:CA Cytophage Technologies Ltd.April 26, 2024 | americanbankingnews.comAvivagen Inc. (OTCMKTS:VIVXF) Short Interest Down 41.2% in AprilApril 29, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 16, 2023 | businesswire.comAvivagen Inc. Announces Results for the First Quarter Ending January 31, 2023May 30, 2022 | financialpost.comAvivagen Signs New Distribution Partner in Vietnam to Support Southeast Asian GrowthMarch 22, 2022 | financialpost.comAvivagen to Attend CEM Sponsored Alpha North ConferenceSee More Headlines Receive VIVXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avivagen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/29/2024Next Earnings (Estimated)6/04/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:VIVXF CUSIPN/A CIKN/A Webwww.avivagen.com Phone613-702-2908FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,710,000.00 Net Margins-645.05% Pretax Margin-645.42% Return on EquityN/A Return on Assets-716.72% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.02 Sales & Book Value Annual Sales$730,000.00 Price / Sales0.68 Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-0.11Miscellaneous Outstanding Shares77,690,000Free Float76,063,000Market Cap$497,216.00 OptionableNot Optionable Beta0.12 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. G. F. Kym Anthony (Age 68)CEO & Vice Chairman Comp: $265.84kDr. Graham Burton Ph.D.Co-Founder, Chief Scientific Officer & DirectorMr. Ira LevyInterim Chief Financial OfficerDr. James Nickerson Ph.D.President and Executive VP of Business Development & Product InnovationMr. Drew BasekDirector of Investor RelationsMs. Tracy Gillett BVSCDirector of Companion Animal & Marketing ManagerMore ExecutivesKey CompetitorsGreen Organic DutchmanOTCMKTS:TGODFBZAMOTCMKTS:BZAMFSpectraScienceOTCMKTS:SCIEChina SXT PharmaceuticalsNASDAQ:SXTCBioasis TechnologiesOTCMKTS:BIOAFView All Competitors VIVXF Stock Analysis - Frequently Asked Questions How have VIVXF shares performed in 2024? Avivagen's stock was trading at $0.0006 on January 1st, 2024. Since then, VIVXF shares have increased by 966.7% and is now trading at $0.0064. View the best growth stocks for 2024 here. Are investors shorting Avivagen? Avivagen saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 14,300 shares, a drop of 41.2% from the March 31st total of 24,300 shares. Based on an average daily volume of 2,000 shares, the days-to-cover ratio is presently 7.2 days. View Avivagen's Short Interest. When is Avivagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our VIVXF earnings forecast. How do I buy shares of Avivagen? Shares of VIVXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:VIVXF) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportProtect Your Bank Account Before It’s Too LateWeiss RatingsTrump is sounding the alarmPreserve GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avivagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.